Cardiotrophin-1: Phase I start

Next quarter, Digna and Biotecnol will start a dose-escalation, Spanish Phase I trial to evaluate 0.3-180 µg/kg doses of IV CT-1 in 33 healthy volunteers. The partners are developing CT-1 under an ame...